RUBIUS THERAPEUTICS
Live / Registered — Registered (as of 22 Sept 2020)
What this means for you
Registered since 22 Sept 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87287699
- Registration number
- 6158400
- Mark type
- Stylized text
- Filed
- 03 Jan 2017
- Published for opposition
- 03 Jul 2018
- Registered
- 22 Sept 2020
- Attorney of record
- Christina M. Licursi, Esq.
Goods and services
- Class 005 — Pharmaceuticals: cells for medical or clinical use for the treatment of a variety of human and animal diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, and other diseases and disorders, namely, central nervous system diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders
- Class 042 — Scientific and technological services: scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals
Owner
- Rubius Therapeutics, Inc., Cambridge, MA, US
- Rubius Therapeutics, Inc., Cambridge, MA, US
- Rubius Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 22 Sept 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 22 Sept 2020 — REGISTERED-PRINCIPAL REGISTER
- 19 Aug 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 18 Aug 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 17 Aug 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Aug 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Aug 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Mar 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Mar 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Mar 2020 — NON-FINAL ACTION E-MAILED
- 10 Mar 2020 — SU - NON-FINAL ACTION - WRITTEN
- 10 Mar 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 26 Feb 2020 — USE AMENDMENT FILED
- 10 Mar 2020 — SOU EXTENSION 3 GRANTED
- 26 Feb 2020 — SOU EXTENSION 3 FILED